Liminal Biosciences Profit Margin

The latest profit margin for LMNL is 71.95% as of June 2023. That compares with 9107.96% in the prior-year period — down 99.2% year over year. That is above the Healthcare sector average of 13.76%. Investors often review this figure alongside Liminal Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, LMNL's profit margin moved from 9107.96% to 71.95% — a 99.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Liminal Biosciences's valuation or profitability profile.

Against Healthcare companies, LMNL currently prints 71.95% for profit margin, while the sector average sits near 13.76%. That is roughly 422.9% above the sector mean. Large gaps often invite a closer look at Liminal Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Liminal Biosciences converts resources into returns. At 71.95%, LMNL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 9107.96% in the prior-year period — down 99.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LMNL's profit margin (71.95%), review year-over-year change from 9107.96%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.